Moreover, bispecific or multifunctional NKCEs were constructed that bridge a TAA on tumor cells with an activating receptor on NK cells such as NKG2D or NKp30 (Colomar‐Carando et al., 2022; Klausz et al., 2022; Klewinghaus et al., 2022; Raynaud et al., 2021). This evidence concerns the gene NCR3 and neoplasm.